Zimbabwe has turned down a major American health deal worth 367 million US dollars (272 million pounds) over five years over Washington's request for confidential biological samples.
This move became public following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa believed the agreement was "unbalanced".
A government spokesperson later clarified that the United States was requesting biological samples for research and commercial purposes but was unwilling to guarantee the resulting advantages from future vaccines.
"We will now turn to the difficult and regrettable task of winding down our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for further negotiations to secure a deal suitable to both sides so the country's critical HIV programme can proceed.
Wider Background
Zimbabwe's decision follows a comparable case in Kenya, where a court halted a related health funding agreement after concerns were filed about the security of Kenyans' medical information.
After resuming office last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had overseen aid for the American government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral agreements to boost openness and accountability.
As per statements, Sixteen African countries have to date signed these new health pacts, constituting more than $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership might have yielded immense advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy via US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to surrender its biological resources and data for a long time, with no corresponding assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Put simply, our country would supply the basic resources for medical research without any certainty that the final treatments would be available to our citizens should a future health crisis arise."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining structures previously established through the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to manage future global health emergencies.
"This framework is intended to guarantee that when a country provides its data, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to develop them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We encourage ongoing discussions with our US partners on how future collaboration could be arranged in a way that honours the sovereignty and interests of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the government's concerns, but urged that negotiations should continue since much of the nation's Aids initiatives depended on external financing.
"If technical issues exist, such as those involving data governance or implementation frameworks, these can often be resolved through detailed discussion and negotiated safeguards," the group added.
This impasse highlights the continuing tensions between accepting vital international aid and safeguarding local interests in an ever more data-driven world.